Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zinc for COVID-19 in outpatients
NCT04621461Phase 4Completed
- Start
- Dec 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of zinc in coronavirus disease 2019 (COVID-19). Primary endpoints: Number of participants hospitalized and/or requiring repeat emergency room visits at 21 days and Number of participants admitted to the Intensive care unit at 30 days. Started Dec 2020; status: completed.
02
Drugs
zinc
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04621461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04621461.